| Literature DB >> 29320993 |
Hsien-Fu Chiu1, Hung-Chun Chen2,3, Kuo-Cheng Lu4,5,6, Kuo-Hsiung Shu7,8,9.
Abstract
BACKGROUND: Despite the development of biomarkers and noninvasive imaging tools, biopsy remains the only method for correctly diagnosing patients with unexplained hematuria, proteinuria and renal failure. Renal biopsy has been performed for several decades in Taiwan; however, a national data registry is still lacking until 2013.Entities:
Keywords: Glomerulonephritis; IgA nephropathy; Renal biopsy
Mesh:
Year: 2018 PMID: 29320993 PMCID: PMC5764016 DOI: 10.1186/s12882-017-0810-4
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Fig. 1The frequency of classification of clinical diagnosis (n = 1467). Nephrotic syndrome, acute kidney injury, and chronic nephritic syndrome were the most common reasons for renal biopsy. RPGN, rapidly progressive glomerulonephritis syndrome
Fig. 2The frequency of different forms of biopsy-proven pathological diagnoses excluding renal transplantation (n = 1281). Primary glomerulonephritides accounted for 48.1%, secondary glomerulonephritides accounted for 36.2%, whereas tubulointerstitial diseases accounted for 12.3%. IgA nephropathy was the most frequent diagnoses among primary glomerulonephritides. On the other hand, diabetic nephropathy and lupus nephritis were the most common among secondary glomerulonephritides
Fig. 3The frequency of biopsy proven primary glomerulonephritides (n = 616). IgA nephropathy, FSGS, MGN and MCD were the most common diagnoses
The clinicopathological correlations of primary glomerular diseases (n = 599)
| Histopathologic diagnosis | NS, | AKI, | CGN, | AGN, | PH, | RPGN, |
|---|---|---|---|---|---|---|
| IgA N | 35 (10.7) | 12 (22.2) | 53 (55.2) | 22 (36.7) | 23 (76.7) | 5 (16.1) |
| MGN | 94 (28.8) | 4 (7.4) | 12 (12.5) | 8 (13.3) | 0 (0.0) | 2 (6.5) |
| MCD | 92 (28.2) | 10 (18.5) | 11 (11.4) | 4 (6.7) | 0 (0.0) | 0 (0.0) |
| FSGS | 81 (24.8) | 14 (25.9) | 11 (11.4) | 8 (13.3) | 5 (16.7) | 2 (6.5) |
| MsPGN | 4 (1.2) | 2 (3.7) | 5 (5.2) | 2 (3.3) | 1 (3.3) | 0 (0.0) |
| CreGN | 4 (1.2) | 6 (11.1) | 2 (2.1) | 6 (10.0) | 1 (3.3) | 17 (54.8) |
| EnPGN | 7 (2.1) | 2 (3.7) | 0 (0.0) | 4 (6.7) | 0 (0.0) | 3 (9.7) |
| MPGN | 9 (2.8) | 4 (7.4) | 2 (2.1) | 6 (10.0) | 0 (0.0) | 2 (6.5) |
| Total | 326 (100.0) | 54 (100.0) | 96 (100.0) | 60 (100.0) | 30 (100.0) | 31 (100.0) |
NS, nephrotic syndrome, AKI acute kidney injury, CGN chronic nephritis syndrome, PH persistent hematuria, AGN acute nephritis syndrome, RPGN rapidly progressive glomerulonephritis syndrome, MCD minimal change disease, MGN membranous nephropathy, MsPGN non-IgA mesangioproliferative glomerulonephritis, MPGN membranoproliferative glomerulonephritis, CreGN crescentic glomerulonephritis, EnGN endocapillary proliferative glomerulonephritis, FSGS focal segmental glomerulosclerosis
Demographic data of the four major primary glomerulonephritides (n = 530)
| MCD ( | FSGS ( | MGN ( | IgAN ( | ||
|---|---|---|---|---|---|
| Age, y | 44.6 ± 18.8 | 50.4 ± 17.1 | 58.1 ± 13.7 | 40.3 ± 14.4 | <0.001 |
| Gender (male, %) | 69 (60.5) | 74 (55.6) | 72 (56.7) | 80 (51.3) | 0.48 |
| DM (n, %) | 13 (11.4) | 19 (14.3) | 16 (12.6) | 18 (11.5) | 0.91 |
| HTN (n, %) | 38 (33.3) | 67 (50.4) | 49 (38.6) | 58 (37.2) | 0.01 |
| HBsAg (n, %) | 5 (4.4) | 10 (7.5) | 7 (5.6) | 11 (7.1) | 0.56 |
| Anti-HCV (n, %) | 2 (1.7) | 4 (3.0) | 5 (3.9) | 0 (0.0) | 0.11 |
Continues variable are represented by mean ± SD or median (interquartile range)
Categorical variables are shown as frequency (%)
Laboratory data and immunologic profile of the four major primary glomerulonephritides (n = 530)
| MCD ( | FSGS ( | MGN ( | IgAN ( | ||
|---|---|---|---|---|---|
| Hemoglobin, g/dL | 13.6 ± 2.3 | 12.4 ± 2.3 | 12.3 ± 2.3 | 12.5 ± 2.4 | <0.001 |
| C3, mg/dL | 116.1 (96.1–138.0) | 111.5 (90.9–133.7) | 106.0 (94.0–126.0) | 108.5 (92.4–125.6) | 0.14 |
| C4, mg/dL | 28.1 (23.2–37.6) | 28.6 (23.3–33.5) | 27.9 (21.4–36.2) | 25.6 (20.3–30.6) | 0.03 |
| IgG, mg/dL | 622.0 (337.0–899.7) | 925.5 (626.7–1235.0) | 632.0 (449.0–834.0) | 1126.0 (938–1366) | <0.001 |
| IgA, mg/dL | 260.4 (201.0–360.5) | 288.5 (233.0–380.2) | 267.0 (213.5–374.2) | 369 (278.0–469.5) | <0.001 |
| IgM, mg/dL | 121.0 (82.4–173.5) | 92.9 (65.4–130.0) | 100.5 (64.1–132.5) | 103.0 (73.4–140.0) | 0.007 |
| IgE, mg/dL | 194.3 (30.5–573.0) | 68.7.0 (23.3–245.5) | 55.4 (23.2–207.0) | 64.0 (19.3–173.0) | 0.04 |
| Cr, mg/dL | 1.0 (0.7–1.6) | 1.5 (0.9–2.5) | 0.9 (0.7–1.7) | 1.2 (0.8–2.1) | <0.001 |
| eGFR, ml/min/1.73m2 | 78.1 (47.2–118.3) | 63.7 (29.7–90.1) | 81.3 (56.9–125.3) | 59.4 (29.8–89.8) | 0.03 |
| Proteinuria, g/day | 7.1 (2.5–12.5) | 3.3 (1.5–7.6) | 6.3 (4.0–10.7) | 1.5 (0.6–2.9) | <0.001 |
| Hematuria ( | 58 (50.8) | 78 (58.6) | 77 (60.6) | 113 (72.4) | 0.02 |
eGFR estimated glomerular filtration rate, calculated by MDRD equation. Continues variable are represented by mean ± SD or median (interquartile range). Categorical variables are shown as frequency (%)
The histopathological spectrum of patients with nephrotic syndrome at different ages (n = 531)
| Pathological diagnosis | 14–24 years | 25–44 years | 45–59 years | >60 years | Total | |
|---|---|---|---|---|---|---|
| MCD | 22 (44.0) | 31 (18.6) | 20 (12.8) | 18 (11.4) | 91 (17.1) | <0.001 |
| IgAN | 7 (14.0) | 15 (8.9) | 10 (6.4) | 2 (1.2) | 34 (6.4) | 0.003 |
| FSGS | 3 (6.0) | 28 (16.7) | 22 (14.1) | 30 (18.9) | 83 (15.6) | 0.15 |
| MGN | 1 (2.0) | 11 (6.6) | 34 (21.8) | 48 (30.4) | 94 (17.7) | <0.001 |
| LN | 11 (22.0) | 31 (18.6) | 15 (9.6) | 3 (1.9) | 60 (11.3) | <0.001 |
| MPGN | 0 (0.0) | 6 (3.6) | 2 (1.3) | 3 (1.9) | 11 (2.1) | 0.33 |
| Renal amyloidosis | 0 (0.0) | 0 (0.0) | 5 (3.2) | 3 (1.9) | 8 (1.5) | 0.08 |
| DM | 0 (0.0) | 21 (12.6) | 27 (17.3) | 28 (17.7) | 76 (14.3) | 0.01 |
| Others | 6 (12.0) | 24 (14.4) | 21 (13.4) | 23 (14.6) | 74 (13.9) | |
| Total | 50 (100.0) | 167 (100.0) | 156 (100.0) | 158 (100.0) | 531 (100.0) |
MCD minimal change disease, MGN membranous nephropathy, MPGN membranoproliferative glomerulonephritis, CreGN crescentic glomerulonephritis, FSGS focal segmental glomerulosclerosis, LN lupus nephritis
International Comparison of Distribution of Primary glomerulonephritis
| Country | Author | Year | Number of biopsies | IgA (%) | MCD (%) | FSGS (%) | MGN (%) | MsPGN (%) | EnPGN (%) | Others (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| China | Zhou (7) | 1993–2007 | 3331 | 54 | 11 | 3 | 15 | 11 | – | 6 |
| Japan | Sugiyama (17) | 2009–2010 | 4132 | 53 | 15 | 6 | 14 | 6 | 1 | 5 |
| Korea | Chang (9) | 1987–2006 | 1346 | 38 | 21 | 8 | 17 | 1 | 5 | 11 |
| Singapore | Woo (6) | 1998–2008 | 786 | 40 | 19 | 15 | 11 | 7 | – | 8 |
| Thailand | Kanjanabuch (16) | 2001–2004 | 506 | 31 | – | 25 | 13 | – | – | 31 |
| Australia | Briganti (13) | 1995–1997 | 1147 | 49 | 6 | 21 | 15 | – | 3 | 6 |
| USA | Sundaraman (11) | 1994–2003 | 195 | 25 | 5 | 20 | 10 | 12 | 8 | 20 |
| Italy | Schena (12) | 1987–1993 | 8287 | 35 | 8 | 12 | 21 | – | – | 25 |
| India | Narasimhan (19) | 1986–2002 | 3845 | 12 | 16 | 24 | 14 | – | – | 34 |
| Saudi Arabia | Mitwalli (15) | 1994–1999 | 127 | 10 | 9 | 35 | 4 | 25 | 16 | 2 |
| Taiwan | Current study | 2013–2015 | 616 | 26 | 18 | 22 | 21 | 3 | 2 | 9 |
MCD minimal change disease, FSGS focal segmental glomerulosclerosis, MGN membranous nephropathy, MsPGN non-IgA mesangioproliferative glomerulonephritis, EnPGN endocapillary proliferative glomerulonephritis
Fig. 4Comparison of frequency of IgA nephropathy in primary glomerular diseases in different countries. Adapted from Zhou et al. [7] with modification